Studies in Drug Developments

Building a Bridge Between Chemistry and Biology - Molecular Forceps that Inhibit the Farnesylation of RAS 

As mentioned above, the generation of new molecular entities by mutation is the rate-limiting step in accessing new biological options. To make efficient use of viable solutions, nature has adopted a modular domain-based approach to building complex proteins. Such an approach is featured in our immune system, that has to be capable of responding to external insults by selecting receptors (antibodies) to 

---

Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs principles and case studies in drug development. Weinheim (Germany) Wiley-VCH 2006. 

Hauschke, D., Steinijans, V., and Pigeot, I., 2007, Bioequivalence studies in drug development Methods and applications, John Wiley Sons. 

One key issue is the requirement for animal testing. The report and recommendations of the European Centre for the Validation of Alternative Methods (ECVAM) workshop (Leahy et al., 1997) clearly state that a major priority is to reduce the number of animals used in pharmacokinetic studies in drug development. As much information as possible should be obtained from alternative sources, such as computer modeling or using data already generated for similar compounds. 

Hauschke D, Steinijans V, Pigeot 1 (2007) Bioequivalence Studies in Drug Development Methods and Applications. John WUey Sons, Ltd, Chichester. 

STAGING AND TYPES OF DRUG METABOLISM STUDIES IN DRUG DEVELOPMENT... 

R. Consonni and M. Veronesi, NMR Screening Methods in Fragment-Based Drug Discovery, in Structure - Activity Relationship Studies in Drug Development by NMR Spectroscopy, ed. Atta-ur-Rahman and M. I. Choudhaiy, Bentham Seienee Publishers Ltd., 2011, vol. 1 p. 67. 

---